Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Mistalin
2. Mistamine
3. Mizolen
4. Mizollen
5. Sl 85.0324
6. Sl-85.0324
7. Zolim
8. Zolistan
1. 108612-45-9
2. Mizollen
3. Zolistan
4. Sl 85.0324
5. Mistamine
6. 2-((1-(1-(p-fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3h)-pyrimidinone
7. Mizolastine (mizollen)
8. Mkc-431
9. Chembl94454
10. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1h-pyrimidin-6-one
11. Mistalin
12. 244o1f90na
13. Mizolastine [inn]
14. Ncgc00181013-01
15. Mizolastina
16. Mizolastinum
17. Mizolen
18. Zolim
19. Dsstox_cid_26801
20. Dsstox_rid_81916
21. Dsstox_gsid_46801
22. 2-((1-(1-(4-fluorobenzyl)-1h-benzo[d]imidazol-2-yl)piperidin-4-yl)(methyl)amino)pyrimidin-4(3h)-one
23. 2-[[1-[1-[(4-fluorophenyl)methyl]benzoimidazol-2-yl]-4-piperidyl]-methyl-amino]-3h-pyrimidin-4-one
24. Mizolastinum [inn-latin]
25. Mizolastina [inn-spanish]
26. Zolistam
27. 2-{1-[1-(4-fluorobenzyl)-1h-benzimidazol-2-yl]-4-piperidyl(methyl)amino}pyrimidin-4(1h)-one
28. Sl-85.0324
29. Mizollen (tn)
30. 2-((1-(1-(4-fluorobenzyl)-1h-benzo[d]imidazol-2-yl)-piperidin-4-yl)(methyl)amino)pyrimidin-4(1h)-one
31. Cas-108612-45-9
32. Mizolastine (jan/inn)
33. Mizolastine [inn:ban]
34. Unii-244o1f90na
35. Ccris 8410
36. Sl 850324
37. Mizolastine [mi]
38. Mizolastine [jan]
39. Schembl5061
40. Mizolastine [mart.]
41. Mizolastine [who-dd]
42. Mls006010068
43. Mkc431
44. Dtxsid5046801
45. Bdbm22877
46. Chebi:31857
47. Gtpl10102
48. Hms3713n04
49. Hy-b0164
50. Tox21_112663
51. Ac-634
52. Mfcd23140913
53. Zinc13831810
54. Akos005145756
55. Akos016003409
56. Tox21_112663_1
57. Ccg-220621
58. Cs-1997
59. Db12523
60. Ks-1139
61. Ncgc00344565-01
62. Ncgc00344565-04
63. 4(1h)-pyrimidinone, 2-((1-(1-((4-fluorophenyl)methyl)-1h-benzimidazol-2-yl)-4-piperidinyl)methylamino)-
64. Sl850324
65. Smr003965484
66. Sl-850324
67. Ft-0628955
68. M2756
69. D01117
70. T71584
71. Ab01566892_01
72. 612m459
73. A801901
74. Q417830
75. J-507624
76. Brd-k21884483-001-01-1
77. (4-ethoxy-2-oxo-2,5-dihydro-pyrrol-1-yl)-aceticacid
78. 2-({1-[1-(4-fluoro-benzyl)-1h-benzoimidazol-2-yl]-piperidin-4-yl}-methyl-amino)-3h-pyrimidin-4-one
79. 2-({1-[1-(4-fluorobenzyl)-1h-benzimidazol-2-yl]-piperidin-4-yl}-methylamino)-4(1h) Pyrimidinone
80. 2-[[1-[1-[(4-fluorophenyl)methyl]-2-benzimidazolyl]-4-piperidinyl]-methylamino]-1h-pyrimidin-6-one
81. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]- Methylamino]-1h-pyrimidin-6-one
82. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methyl-amino]-1h-pyrimidin-6-one
| Molecular Weight | 432.5 g/mol |
|---|---|
| Molecular Formula | C24H25FN6O |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 432.20738760 g/mol |
| Monoisotopic Mass | 432.20738760 g/mol |
| Topological Polar Surface Area | 65.8 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 728 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
R06AX25
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AX - Other antihistamines for systemic use
R06AX25 - Mizolastine
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
ABOUT THIS PAGE
A Mizolastine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mizolastine, including repackagers and relabelers. The FDA regulates Mizolastine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mizolastine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mizolastine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mizolastine supplier is an individual or a company that provides Mizolastine active pharmaceutical ingredient (API) or Mizolastine finished formulations upon request. The Mizolastine suppliers may include Mizolastine API manufacturers, exporters, distributors and traders.
click here to find a list of Mizolastine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Mizolastine written confirmation (Mizolastine WC) is an official document issued by a regulatory agency to a Mizolastine manufacturer, verifying that the manufacturing facility of a Mizolastine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Mizolastine APIs or Mizolastine finished pharmaceutical products to another nation, regulatory agencies frequently require a Mizolastine WC (written confirmation) as part of the regulatory process.
click here to find a list of Mizolastine suppliers with Written Confirmation (WC) on PharmaCompass.
Mizolastine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mizolastine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mizolastine GMP manufacturer or Mizolastine GMP API supplier for your needs.
A Mizolastine CoA (Certificate of Analysis) is a formal document that attests to Mizolastine's compliance with Mizolastine specifications and serves as a tool for batch-level quality control.
Mizolastine CoA mostly includes findings from lab analyses of a specific batch. For each Mizolastine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mizolastine may be tested according to a variety of international standards, such as European Pharmacopoeia (Mizolastine EP), Mizolastine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mizolastine USP).
LOOKING FOR A SUPPLIER?
